➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
AstraZeneca
McKesson
Johnson and Johnson
Boehringer Ingelheim

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 6,030,775

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,030,775
Title: Methods and reagents for typing HLA Class I genes
Abstract:Consensus sequences of introns 1, 2 and 3 from the majority of HLA-A, -B and -C allotypes are identified and used to develop primers located within introns 1 and 3 of the HLA-A, HLA-B and HLA-C genes. These primers are suitable for locus-specific amplification of the entirety of exons 2 and 3, i.e., the portion of these of genes most suitable for use in typing of HLA-A, HLA-B and HLA-C. These primers are also suitable for use as sequencing primers to determine the HLA alleles in sequence-based HLA typing. Thus, the primers can be used for testing a sample to determine the HLA-A, -B or -C type of the sample by treating the tissue sample to obtain nucleic acid polymers suitable for amplification; combining the nucleic acid polymers with a first primer which is complementary to a portion of intron 1 or intron 3 of the HLA gene, and a second primer which is complementary to some other portion of the HLA gene under conditions suitable for amplification to obtain an amplified product; and evaluating the amplified product to determine the allelic type of the HLA-A, HLA-B or HLA-C genes. Preferably, at least one of the amplification primers has a sequence which provides locus-specific amplification.
Inventor(s): Yang; Soo Young (New York, NY), Cereb; Nezih (New York, NY)
Assignee:
Application Number:08/577,081
Patent Claims:see list of patent claims

Details for Patent 6,030,775

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Moodys
Boehringer Ingelheim
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.